Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a
clinical-stage TechBio company specializing in developing
AI-Immunology™-powered vaccines, is proud to announce that it will
be presenting clinical readouts on its two personalized cancer
vaccine trials at SITC’s 38th annual meeting, taking place in San
Diego, California from November 1-5, 2023.
The results will be presented in two
posters:
1. Title: “AI-designed
personalized neoantigen vaccine, EVX-02, induces robust T-cell
responses in melanoma patients”
Poster #:
623Location: Exhibit Hall B – San Diego Convention
CenterTime: Friday, November 3, 9 a.m. - 7 p.m.
PDT
This poster will be presented by Evaxion’s
senior project manager, Daniela Kleine-Kohlbrecher. The abstract
was also selected by the SITC Communications Committee to be
presented at the SITC 2023 Annual Meeting Press Conference,
scheduled for Wednesday, November 1, from 12:00–1:30 p.m. PDT.
2. Title: “Effects of an
AI-generated personalized neopeptide-based immunotherapy, EVX-01,
in combination with pembrolizumab in patients with metastatic
melanoma. A clinical trial update”
Poster #: 782-H
Location: Exhibit Hall B – San Diego Convention
CenterTime: Saturday, November 4, 9 a.m. - 8:30
p.m. PDT
This poster will be presented by principal
investigator Professor Adnan Khattak from the Hollywood Private
Hospital in Nedlands, Australia.
Christian Kanstrup, Chief Executive Officer at
Evaxion, commented, “We are thrilled about the continuous buildup
of positive clinical evidence for the unique predictive
capabilities of our AI-immunology™ platform, which we believe holds
promise for truly groundbreaking cancer treatments.”
Birgitte Rønø, Chief Scientific Officer at
Evaxion, expressed her enthusiasm about the upcoming conference,
stating, “We are looking forward to sharing these promising
clinical trial results with the SITC community, showcasing the
advantages of our AI-Immunology™ platform to design personalized
cancer vaccines. We believe this takes us one step closer to
bringing novel treatments to the market and meeting the pressing
global medical need for cancer patients.”
About EVX-01 Phase 2 Clinical
Trial EVX-01 is Evaxion’s lead clinical asset and
constitutes a peptide-based personalized cancer vaccine. The Phase
2 clinical study is a self-sponsored open-label, single-arm,
multi-center trial carried out in collaboration with Merck Sharp
& Dohme LLC, together with leading principal investigators and
research centers from Italy and Australia, and aims at evaluating
the efficacy and safety of EVX-01 vaccination in combination with
anti-PD1 treatment (pembrolizumab) in treatment-naive patients with
metastatic or unresectable malignant stage III or IV melanoma. More
information can be accessed under clinical trial ID
NCT05309421.
About EVX-02 Phase 1/2a
Clinical Trial
The EVX-02 Phase 1/2a represents Evaxion’s
first-in-human DNA-based personalized cancer vaccine study. This
open-label, multi-center study aims at assessing the safety,
tolerability, pharmacodynamic responses, and efficacy of EVX-02
neoantigen vaccine and anti-PD-1 treatment (nivolumab) in patients
who have had a complete resection of a Stage IIIB/IIIC/IIID or
Stage IV melanoma with risk of recurrence. More information can be
accessed under clinical trial ID NCT04455503.
About EVAXIONEvaxion Biotech
A/S is a pioneering TechBio company based upon its AI platform:
AI-immunology™. Evaxion’s proprietary and scalable AI prediction
models harness the power of artificial intelligence to decode the
human immune system and develop novel immunotherapies for cancer,
bacterial diseases, and viral infections. Based upon
AI-immunology™, Evaxion has developed a clinical-stage oncology
pipeline of novel personalized vaccines and a preclinical
infectious disease pipeline in bacterial and viral diseases with
high unmet medical needs. Evaxion is committed to transforming
patients’ lives by providing innovative and targeted treatment
options. For more information about Evaxion and its groundbreaking
AI-immunology™ platform and vaccine pipeline, please visit our
website.
Forward-Looking
StatementThis announcement contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. The words “target,” “believe,” “expect,”
“hope,” “aim,” “intend,” “may,” “might,” “anticipate,”
“contemplate,” “continue,” “estimate,” “plan,” “potential,”
“predict,” “project,” “will,” “can have,” “likely,” “should,”
“would,” “could,” and other words and terms of similar
meaning identify forward-looking statements. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various factors, including, but not
limited to, risks related to: our financial condition and need for
additional capital; our development work; cost and success of our
product development activities and preclinical and clinical trials;
commercializing any approved pharmaceutical product developed using
our AI platform technology, including the rate and degree of market
acceptance of our product candidates; our dependence on third
parties including for conduct of clinical testing and product
manufacture; our inability to enter into partnerships; government
regulation; protection of our intellectual property rights;
employee matters and managing growth; our ADSs and ordinary
shares, the impact of international economic, political, legal,
compliance, social and business factors, including inflation, and
the effects on our business from the worldwide ongoing COVID-19
pandemic and the ongoing conflict in the region
surrounding Ukraine and Russia and the Middle East; and other
uncertainties affecting our business operations and financial
condition. For a further discussion of these risks, please refer to
the risk factors included in our most recent Annual Report on Form
20-F and other filings with the U.S. Securities and Exchange
Commission (SEC), which are available
at www.sec.gov. We do not assume any obligation to
update any forward-looking statements except as required by
law.
Contact Information
Evaxion Biotech A/S
Christian Kanstrup
Chief Executive Officer
cka@evaxion-biotech.com
Source: Evaxion Biotech
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Apr 2024 to May 2024
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From May 2023 to May 2024